The total population also included patients also being treated with Pfizer’s blockbuster ATTR-cardiomyopathy drug Vyndamax (tafamidis meglumine) at baseline, and vutrisiran performed even better ...

The market for ATTR therapies is very large, with Pfizer’s tafamidis-based products Vyndamax and Vyndaqel (tafamidis) growing 39% last year to more than $3.3 billion. The oral, daily ...

The approval pits the small biotech’s drug against Pfizer’s Vyndaqel and Vyndamax, two drugs that use the same active ingredient, tafamidis ... a twice-daily pill — ahead of Pfizer ...